The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines.
Source: Yahoo Finance
Late-stage biotech Novavax ( NVAX) has announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.
NVX‑CoV2373 is a stable, prefusion protein made using the company’s nanoparticle technology and Matrix‑M adjuvant, which is designed to enhance the immune response and stimulate high levels of neutralizing antibodies.
Dr. Shabir Madhi, Professor of Vaccinology at Wits University, will lead the clinical trial, which is supported in part by a $15 million grant from the Bill & Melinda Gates Foundation.
“Because South Africa is experiencing a winter surge of COVID-19 disease, this important Phase 2b clinical trial has the potential to provide an early indication of efficacy, along with additional safety and immunogenicity data for NVX-CoV2373,” said Gregory M. Glenn of Novavax.
The randomized, observer-blinded, placebo-controlled Phase 2b clinical trial of NVX-CoV2373 will include two cohorts. One cohort will evaluate efficacy, safety and immunogenicity in approximately 2,665 healthy adults.
Meanwhile the second cohort will evaluate safety and immunogenicity in approximately 240 medically stable, HIV-positive adults. This allows for evaluation of the vaccine across a diverse, representative study population, the company says.
Novavax expects that, if approved in South Africa, its COVID-19 vaccine would ultimately be supplied to South Africa through Novavax’ recently announced collaboration with the Serum Institute of India.
“The major motivation for the COVID-19 vaccines being evaluated at an early stage in South Africa is to generate evidence in the African context on how well these vaccines work in settings such as our own,” said Shabir Madhi.
In the Phase 1 portion of the Phase 1/2 clinical trial, conducted in Australia, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.
Phase 2 clinical trials will begin in August. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $388 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).
In the run-up to developing a coronavirus vaccine candidate, the stock has exploded by over 3,580%. B.Riley FBR analyst Mayank Mamtani recently reiterated a Buy rating on the stock with a $257 price target (75% upside potential).
“We anticipate NVAX continuing to secure supply agreements to secure region specific demand, totaling in ~2-3 billion ‘2373 doses delivered in 2021-22 timeframe,” Mamtani told investors.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
Novavax starting human trial of its vaccine in Australia
Kaiser Permanente launches first coronavirus vaccine trial
Corona Fear’s Cure: Chanting from the Bible and the Quran
Can You Chant from the Bible or the Quran to Bliss and Happiness?
Japanese flu drug ‘clearly effective’ in treating coronavirus, says China
Synthetic antibodies might offer a quick coronavirus treatment
The Four Possible Timelines for Life Returning to Normal
The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic
Coronavirus: TB Vaccination Trial Started in Melbourne, Australia
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
All of humanity are intimate neighbors: Coronavirus proves it once again
Praise be to God for the Miracle of Our Immune System
USA: 15-minute coronavirus test is here
Does the Ordinary Soap Kill Coronavirus?
Here’s a list of disinfectants you can use against coronavirus
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE
Coronavirus Vaccine Tracker – The New York Times
Categories: The Muslim Times, Vaccine
The Phase 2 study will test the safety and efficacy of the vaccine in South Africa, with 2,665 healthy adults and another 240 who are HIV positive
…
Novavax’s vaccine consists of two shots given 21 days apart. The shots deliver a protein resembling the spike jutting out from the new coronavirus to trigger the production of antibodies and immune cells that fight off the virus. The shots also contain a component, called an adjuvant, to boost the immune response.
The Gaithersburg, Md., company said it plans to provide the data collected from the South Africa trial to the U.S. Food and Drug Administration as part of the evidence on its vaccine candidate.
The company also said it plans to start a second midstage trial in the near future in Australia and the U.S.
https://www.wsj.com/articles/covid-19-vaccine-candidate-from-novavax-starts-midstage-trial-11597645503
Goldman’s economists expect at least one COVID-19 vaccine will be approved by the end of this year, putting the U.S. economy on track to grow 6.4% in 2021, better than the 3.9% growth expected by the consensus. Kostin sees the S&P 500 reaching 3,800 over the next 12 months.
https://finance.yahoo.com/news/stocks-surge-coronavirus-vaccine-boosts-152742785.html
Reblogged this on Alexanders' Blog.